N6-Methyladenosine (m6A) is an abundant post-transcriptional RNA modification that is found in various classes of eukaryotic or viral RNA, including mRNA, rRNA, tRNA, snRNA, microRNA (miRNA), and long non-coding RNA (lncRNA).{58224,58223} m6A modifications are enriched near stop codons of mRNA transcripts, increasing along the length of the coding region and decreasing after 3’-UTRs.{58224,58225} m6A formation is a reversible process that occurs primarily in the nucleus.{58226} Its formation is catalyzed by a methyltransferase complex that is composed of the writers METTL3 and METTL14, which preferentially methylate RNA substrates with a GGACU domain, and the accessory protein Wilms tumor 1-associating protein (WTAP), which recruits target RNAs.{58224} m6A demethylation is mediated by the erasers fat mass and obesity-associated (FTO) protein and ALKBH5. Upon export into the cytosol, m6A modifications are recognized by a variety of reader proteins, including YTH-domain family (YTHDF) members, which regulate RNA translation. m6A modifications regulate multiple steps of RNA processing, including pre-mRNA splicing, nuclear export, translation, and decay, influencing a variety of critical cellular functions, such as differentiation, neurodevelopment, immunity, and oncogenesis.{58224,58223,58227} Global m6A mRNA levels are decreased in tumor tissue isolated from patients with endometrial cancer.{58228} Cayman’s N6-Methyladenosine Rabbit Monoclonal Antibody can be used for dot blot (DB), ELISA, and methylated RNA immunoprecipitation (MeRIP) applications.